Best Options Strategy for PCVX
Looking for the best options strategy for Vaxcyte, Inc. (PCVX)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live PCVX option chain right now, and a simple map from your view on PCVX to the strategy that fits it. Model any of them in the calculator before you trade.
About PCVX
Vaxcyte, Inc. (PCVX) is a major company in Biotechnology. Options traders on PCVX tend to watch , since these can drive large moves in the share price.
About Vaxcyte, Inc.
Vaxcyte develops vaccines aimed at preventing or treating bacterial infections, primarily focusing on pneumococcal disease and related conditions. The company's core pipeline centers on pneumococcal conjugate vaccines (PCVs) designed using a carrier-sparing technology platform. Its most advanced candidate, VAX-24, targets invasive pneumococcal disease in infants and covers 24 serotypes, while VAX-31 extends to 31 serotypes for older populations. Beyond pneumococcal work, Vaxcyte is advancing VAX-A1 for Group A Streptococcus prevention, VAX-PG as a protein vaccine against periodontitis, and VAX-GI for Shigella-caused dysentery. The company also has a third-generation pneumococcal vaccine in development called VAX-XL. Founded in 2013 and based in San Carlos, California, Vaxcyte was previously known as SutroVax before rebranding in 2020.
As a clinical-stage biotech company, Vaxcyte does not currently generate revenue from product sales. The company operates in the global vaccine market, which includes both infant immunization programs and adult preventive health segments. Its financial model depends on advancing candidates through clinical trials, securing partnerships or licensing…
Today's top-scoring strategy for PCVX
Our engine ranks defined-risk strategies on the live PCVX chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $52.5 | $0.13 |
| Sell | 1× | PUT | $55 | $0.49 |
| Sell | 1× | CALL | $60 | $0.57 |
| Buy | 1× | CALL | $65 | $0.03 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at PCVX's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
PCVX is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on PCVX currently price in about 32% implied volatility, versus roughly 45% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$3.64 (±6%) in PCVX by 2026-07-17 — a range of roughly $53.94 to $61.22. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on PCVX trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Earnings & IV crush
PCVX's next earnings report is due around August 5, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $8.4B
- Beta (vs market)
- 1.24
- 52-week range
- $29.08–$65.00 (79% up the range)
- Short interest
- 10.2% of float · 9.8 days to cover
With 10.2% of PCVX's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for PCVX
Start with your outlook on PCVX, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while PCVX stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open PCVX in the free calculator →
Frequently asked questions
What is the best options strategy for PCVX?
It depends on your outlook. Bullish traders often use a long call or bull call spread on PCVX; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are PCVX options liquid enough to trade?
Vaxcyte, Inc. (PCVX) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade PCVX options?
Buying a single PCVX call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade PCVX or any security. Do your own research.
What does Vaxcyte, Inc. do?
Vaxcyte, Inc. (PCVX) operates in the Biotechnology industry. The "About Vaxcyte, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Vaxcyte, Inc. pay a dividend?
Vaxcyte, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Vaxcyte, Inc. next report earnings?
Vaxcyte, Inc.'s next earnings are expected around August 5, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to PCVX
Comparing PCVX with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 825 Industrial Road, Suite 300, San Carlos, CA, 94070, United States
- Industry
- Biotechnology
- Employees
- 507
- CEO
- Mr. Grant E. Pickering M.B.A.
- Phone
- 650 837 0111
- Website
- vaxcyte.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.